Response Biomedical, Roche to take CV tests to North America
This article was originally published in Clinica
Executive Summary
Roche Diagnostics is set to take Response Biomedical’s line of cardiovascular point-of-care tests to the North American market. The two firms have entered an exclusive agreement that will see Roche make Response’s RAMP 200 (rapid analyte measurement platform) tests for Troponin-I, CK-MB, Myoglobin and NT-proBNP available in the US, Canadian and other unnamed markets. According to Roche, the RAMP tests provide physicians with what it calls improved “vein-to-brain” time, allowing faster treatment times. Roche had previously gained worldwide rights to the line in June for an undisclosed fee. Financial details of this deal were also not revealed.